Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. Remon, J., Isla, D., Garrido, P., de Castro, J., Majem, M., Viñolas, N., Artal, A., Carcereny, E., García-Campelo, M. R., Lianes, P., Provencio, M., Juan, O., Diz, P., Blanco, R., Lopez-Castro, R., Maestu, I., Vadell, C., & Felip, E. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 19(12):1537–1542, 2017.
doi  abstract   bibtex   
BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women. CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.
@article{remon_efficacy_2017,
	title = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting: the {WORLD07} database},
	volume = {19},
	issn = {1699-3055},
	shorttitle = {Efficacy of tyrosine kinase inhibitors in {EGFR}-mutant lung cancer women in a real-world setting},
	doi = {10.1007/s12094-017-1700-8},
	abstract = {BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.
METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.
RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4\% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60\%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.
CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.},
	language = {eng},
	number = {12},
	journal = {Clinical \& Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico},
	author = {Remon, J. and Isla, D. and Garrido, P. and de Castro, J. and Majem, M. and Viñolas, N. and Artal, A. and Carcereny, E. and García-Campelo, M. R. and Lianes, P. and Provencio, M. and Juan, O. and Diz, P. and Blanco, R. and Lopez-Castro, R. and Maestu, I. and Vadell, C. and Felip, E.},
	year = {2017},
	pmid = {28660482},
	keywords = {Advanced, Article, EGFR mutant, NSCLC, Oncologia, TKI, Women},
	pages = {1537--1542},
}

Downloads: 0